Factors associated with plasma antigen carbohydrate 125 and amino-terminal pro-B-type natriuretic peptide concentrations in acute heart failure
Tóm tắt
Plasma amino-terminal pro-B-type natriuretic peptide and antigen carbohydrate 125 levels are positively associated with a higher risk of adverse clinical outcomes in acute heart failure. As a proxy of congestion, antigen carbohydrate 125 has also been proposed as a right-sided heart failure marker. Thus, we aimed to determine in this population the main factors – including echocardiographic right-sided heart failure parameters – associated with antigen carbohydrate 125 and amino-terminal pro-B-type natriuretic peptide.
We prospectively included 2949 patients admitted with acute heart failure. Amino-terminal pro-B-type natriuretic peptide and antigen carbohydrate 125 were used as dependent variables in a multivariable linear regression analysis. The mean age of the sample was 73.9±11.1 years; 48.9% were female, 35.8% showed ischaemic aetiology, and 51.6% exhibited heart failure with preserved ejection fraction. The median (interquartile range) for amino-terminal pro-B-type natriuretic peptide and antigen carbohydrate 125 were 4840 (2111–9204) pg/ml and 58 (26–129) U/ml, respectively. In a multivariable setting, and ranked in order of importance (R2), estimated glomerular filtration rate (43.7%), left ventricle ejection fraction (15.1%), age (12.4%) and high-sensitivity troponin T (10.9%) emerged as the most important factors associated with amino-terminal pro-B-type natriuretic peptide. The five main factors associated with antigen carbohydrate 125 were, in order of importance: the presence of pleural effusion (36.8%), tricuspid regurgitation severity (25.1%), age (11.9%), amino-terminal pro-B-type natriuretic peptide (6.5%) and peripheral oedema (4.3%).
In patients with acute heart failure the main factors associated with amino-terminal pro-B-type natriuretic peptide were renal dysfunction, left ventricle ejection fraction and age. For antigen carbohydrate 125, clinical parameters of congestion and the severity of tricuspid regurgitation were the most important predictors. These results endorse the value of antigen carbohydrate 125 as a useful marker of right-sided heart failure.
Từ khóa
Tài liệu tham khảo
Núñez, 2012, Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of acute heart failure, Int J Cardiol, 159, 21, 10.1016/j.ijcard.2011.02.001
Núñez, 2017, Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure, Eur Heart J Acute Cardiovasc Care, 6, 685, 10.1177/2048872616649757
Núñez, 2014, Clinical utility of antigen carbohydrate 125 in heart failure, Heart Fail Rev, 19, 575, 10.1007/s10741-013-9402-y
Núñez, 2010, Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure, Eur Heart J, 31, 1752, 10.1093/eurheartj/ehq142
Mueller, 2019, Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations, Eur J Heart Fail, 21, 715, 10.1002/ejhf.1494
Núñez, 2011, Antigen carbohydrate 125 in heart failure: Not just a surrogate for serosal effusions?, Int J Cardiol, 146, 473, 10.1016/j.ijcard.2010.12.027
Miñana, 2010, CA125 and immunoinflammatory activity in acute heart failure, Int J Cardiol, 145, 547, 10.1016/j.ijcard.2010.04.081
Núñez, 2007, Carbohydrate antigen 125: An emerging prognostic risk factor in acute heart failure?, Heart, 93, 716, 10.1136/hrt.2006.096016
Yilmaz, 2011, Plasma CA-125 level is related to both sides of the heart: A retrospective analysis, Int J Cardiol, 149, 80, 10.1016/j.ijcard.2009.12.003
Nägele, 1999, CA125 and its relation to cardiac function, Am Heart J, 137, 1044, 10.1016/S0002-8703(99)70360-1
Yilmaz, 2011, Role of CA-125 in identification of right ventricular failure in chronic obstructive pulmonary disease, Clin Cardiol, 34, 244, 10.1002/clc.20868
McMurray, 2012, ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC, Eur Heart J, 33, 1787, 10.1093/eurheartj/ehs104
Ponikowski, 2016, ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur Heart J, 37, 2129, 10.1093/eurheartj/ehw128
Lang, 2005, Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: A report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology, J Am Soc Echocardiogr, 18, 1440, 10.1016/j.echo.2005.10.005
Rudski, 2010, Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography, J Am Soc Echocardiogr, 23, 685, 10.1016/j.echo.2010.05.010
Hogenhuis, 2007, Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure, Eur J Heart Fail, 9, 787, 10.1016/j.ejheart.2007.04.001
Bayes-Genis, 2007, Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea, Arch Intern Med, 167, 400, 10.1001/archinte.167.4.400
Januzzi, 2006, NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients: The international collaborative of NT-proBNP Study, Eur Heart J, 27, 330, 10.1093/eurheartj/ehi631
Charmetant, 2019, Impact of age and renal function on usefulness of NT-proBNP to diagnose heart failure, Clin Nephrol, 92, 65, 10.5414/CN109480
Brunner-La Rocca, 2015, Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials, Eur J Heart Fail, 17, 1252, 10.1002/ejhf.401
Vergaro, 2019, Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction, Int J Cardiol, 296, 91, 10.1016/j.ijcard.2019.08.040
Kang, 2015, KorHF Registry. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF, Heart, 101, 1881, 10.1136/heartjnl-2015-307782
Verschuren, 2013, The prognostic value of pro-B-Type natriuretic peptide in acute pulmonary embolism, Thromb Res, 131, e235, 10.1016/j.thromres.2013.03.009
Lankeit, 2014, Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism, Eur Respir J, 43, 1669, 10.1183/09031936.00211613
Gheorghiade, 2010, European Society of Cardiology; European Society of Intensive Care Medicine. Assessing and grading congestion in acute heart failure: A scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine, Eur J Heart Fail, 12, 423, 10.1093/eurjhf/hfq045
Peacock, 2010, Current techniques of fluid status assessment, Contrib Nephrol, 164, 128, 10.1159/000313726
Núñez, 2012, Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure, Eur J Heart Fail, 14, 540, 10.1093/eurjhf/hfs013
Desai, 2013, Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: The art of medicine remains long, Circulation, 127, 509, 10.1161/CIRCULATIONAHA.112.120493
Llàcer, 2019, Carbohydrate antigen 125 in heart failure. New era in the monitoring and control of treatment, Med Clin (Barc), 152, 266, 10.1016/j.medcli.2018.08.020
Hahn, 2019, Anatomic relationship of the complex tricuspid valve, right ventricle, and pulmonary vasculature: A review, JAMA Cardiol, 4, 478, 10.1001/jamacardio.2019.0535
Núñez, 2016, CHANCE-HF Investigators. Carbohydrate antigen-125-guided therapy in acute heart failure: CHANCE-HF: A randomized study, JACC Heart Fail, 4, 833, 10.1016/j.jchf.2016.06.007